Regeneron Pharmaceuticals (REGN) Accounts Payables (2009 - 2026)

Regeneron Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Accounts Payables rose 45.58% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 45.58% YoY), while the FY2025 annual figure was $939.0 million, up 18.94% from the prior year.
• Accounts Payables was $1.0 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $939.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.0 billion in Q1 2026 to a low of $470.3 million in Q1 2022.
• Historically, Accounts Payables has averaged $661.1 million across 5 years, with a median of $599.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables retreated 13.37% in 2022, then surged 81.74% in 2025.
• A 5-year view of Accounts Payables shows it stood at $589.2 million in 2022, then climbed by 2.95% to $606.6 million in 2023, then jumped by 30.15% to $789.5 million in 2024, then climbed by 18.94% to $939.0 million in 2025, then rose by 9.38% to $1.0 billion in 2026.
• The last three Accounts Payables figures came in at $1.0 billion (Q1 2026), $939.0 million (Q4 2025), and $903.8 million (Q3 2025), per Business Quant data.